Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis

por Correll, Christoph U, Højlund, Mikkel, Graham, Christine, Todtenkopf, Mark S, McDonnell, David, Simmons, Adam
Publicado 2023

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

por Citrome, Leslie, McEvoy, Joseph P, Todtenkopf, Mark S, McDonnell, David, Weiden, Peter J
Publicado 2019

Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”

por Todtenkopf, Mark S., Correll, Christoph U., Harris-White, Marni E., Doane, Michael J., McDonnell, David
Publicado 2023

Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches

por Peciña, Marta, Karp, Jordan F., Mathew, Sanjay, Todtenkopf, Mark S., Ehrich, Elliot W., Zubieta, Jon-Kar
Publicado 2018

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates

por Cunningham, Jacobi I, Eyerman, David J, Todtenkopf, Mark S, Dean, Reginald L, Deaver, Daniel R, Sanchez, Connie, Namchuk, Mark
Publicado 2019

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder

por Citrome, Leslie, Graham, Christine, Simmons, Adam, Jiang, Ying, Todtenkopf, Mark S, Silverman, Bernard, DiPetrillo, Lauren, Cummings, Hannah, Sun, Lei, McDonnell, David
Publicado 2021